Article Sidebar
Views pdf: 41
COST-EFFECTIVENESS ANALYSIS OF ANTIBIOTICS IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN VIETNAM
Main Article Content
Abstract
Background: Multi-resistant gram-negative bacteria present a significant challenging in hospital-acquired infections, including complicated intra-abdominal infections (cIAI). The combination of ceftazidime/avibactam (CEF/AVI, acknowledge for its efficacy, has obtained approvals from the US Food and Drug Administration and the European Medicines Agency for the treatment of cIAI (1, 2). Despite its effectiveness, the high costs acts as a considerable barrier to clinical prescription. Research methods: This research employs a modeling approach utilizing a sequential simulation model of multi-resistant gram-negative bacterial infections to analyze cost-effectiveness based on the perspective of Vietnamese healthcare payer. Input parameters for the model were derived from data collected through clinical research, systematic review analysis, retrospective examination of health insurance payment data in research hospitals, and insights collected from consultations with expert interview. Results: ICER of CEF/AVI ranges from 95.70 - 114.27 million VND/QALY when compared with other regimens with the same indication. Compared with the threshold of 3 times GDP, CEF/AVI is cost-effective in the treatment of complicated intra-abdominal infections – cIAI when compared with existing regimens. Conclusion: Based on the perspective of Vietnamese healthcare payer, compared to the willingness-to-pay threshold of 3 times the GDP per capita income in 2023 (305.7 million VND), CEF/AVI is cost-effective in the treatment of cIAI in Vietnam.
Article Details
Keywords
antibiotics, complicated intra-abdominal infection, cIAI, cost-effectiveness
References
2. European Medicines Agency. (2016, 11/09/2023). Zavicefta: EPAR - Medicine overview. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta
3. M. Sartelli et al., "WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections," (in eng), World journal of emergency surgery, vol. 16, no. 1, pp. 1-48, 2021.
4. M. Sartelli et al., "Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study," (in eng), World Journal of Emergency Surgery, vol. 9, no. 1, pp. 1-10, 2014.
5. S. Blot and J. J. De Waele, "Critical issues in the clinical management of complicated intra-abdominal infections," (in eng), Drugs, vol. 65, pp. 1611-1620, 2005.
6. T. Kongnakorn et al., "Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)," (in eng), Antimicrobial Resistance Infection Control, vol. 8, no. 1, pp. 1-15, 2019.
7. R. Hutubessy, D. Chisholm, and T. T.-T. Edejer, "Generalized cost-effectiveness analysis for national-level priority-setting in the health sector," (in eng), Cost effectiveness and resource allocation, vol. 1, no. 1, pp. 1-13, 2003.
8. M. F. Drummond, M. J. Sculpher, K. Claxton, G. L. Stoddart, and G. W. Torrance, Methods for the economic evaluation of health care programmes. Oxford university press, 2015.